Japanese pharmaceutical company focused on rare/orphan diseases, urology and respiratory drugs.
Japanese pharmaceutical company focused on rare/orphan diseases, urology and respiratory drugs.
Sells prescription drugs to hospitals and specialist doctors, largely in Japan, and earns outside Japan through its US subsidiary NS Pharma, which markets Viltepso for Duchenne muscular dystrophy. A smaller functional-food ingredients business sits alongside the drugs.
In one line: A mid-size Japanese pharma with a rare-disease focus, like a smaller Alexion.
Moat: narrow (IP / patents, regulatory licence). Orphan-drug designations and patents provide extended exclusivity in niche therapeutic areas.
Headquarters: Kyoto, Japan · Founded: 1919 · Employees: 2,309
Size Nippon Shinyaku (4516.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.42B, the 591st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,377 on 18 Nov 2026.
Performance Over six months the shares fell 20.3%, against -9.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 17.7% over the last twelve months (peer median +11.3%); the operating margin is 17.8% (peer median 10.2%).
Valuation It trades at 7.9× forward earnings against a peer median of 23.2× (cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -25 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥189B | ¥171B | ¥160B | ¥148B | ¥144B |
| Revenue growth | — | +7% | +8% | +3% | — |
| Gross profit | ¥122B | ¥112B | ¥108B | ¥97.0B | ¥87.3B |
| EBITDA | ¥40.6B | ¥39.7B | ¥42.8B | ¥36.4B | ¥34.3B |
| Net income | ¥29.4B | ¥29.7B | ¥32.6B | ¥25.9B | ¥22.8B |
| Free cash flow | ¥23.0B | ¥24.2B | ¥32.8B | ¥11.2B | ¥20.5B |
| Capital expenditure | ¥13.0B | ¥3.78B | ¥34.8B | ¥9.65B | ¥11.7B |
| Total debt | ¥3.33B | ¥2.57B | ¥2.72B | ¥2.87B | ¥2.66B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Nippon Shinyaku 4516.T | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% |
| ONO Pharmaceutical 4528.T | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4516.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.3% | -3.7% | 9th highest of 20 |
| 6-month return | -20.3% | -9.1% | 7th lowest of 20 |
| Distance from 52-week high | -48.3% | -40.0% | 8th lowest of 20 |
| Revenue growth (TTM) | +17.7% | +11.3% | 5th highest of 19 |
| Operating margin | 17.8% | 10.2% | 6th highest of 19 |
| Forward P/E | 7.9× | 23.2× | cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -18.1% | 3.9% | least demanding of 10 |
| Growth delivered (Del g) | +7.0% | +16.6% | 4th lowest of 10 |
| Hurdle (Req g minus delivered) | -25.1 pp | -7.9 pp | least demanding of 10 |
| ROIC minus cost of capital | +5.5 pp | -1.8 pp | 6th highest of 20 |
| EV / EBITDA | 3.9× | 17.6× | cheapest of 5 |
| Net debt / EBITDA | -1.7× | 0.3× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 27.2× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |